[Reprint] 300158 Shanxi Zhendong pharmaceutical and a reserve rich herbal unit _wenyicissy_ Sina Blog

Original adinjury lawyers orlandodress: Shanxi Zhendong pharmaceuticbill consolidation loan mortgage second al and a reserve rich herbal unit " > 300158 pharsan francisco personal injury attorneys maceutical Shanxi Zhendong another reserve rich herbal shares author: fattened cattle investment earnings forecast: expected 10 ~ 12 year net profit growth of 35% and 57%, 30%, EPS (diluted) 0.64, 1.00, 1.30 Yuan/unit key ideas: 1. the company mainly profitable varieties of Matrine injection for cancer pain and bleeding, 09 annual sales, gross margin 3.7 million up to 96 per cent of total income and gross margin accounted for more than 71%, 87%, domestic exclusive, is the protection of national herbal medicine and the national CPI Medicare varieties. Compared to similar products in Japan are lower cost, increase the amount of applications for clinical trials are expected to be the fastest of 12 years at the end of the second level above hospital cover less than 50%, it is expected that the future can still maintain rapid growth. 2. the effect of digital marketing integration, the second line of products was good. 07, 09, acquisitions Taisheng pharmacy, Kaiyuan pharmaceutical, to extend the product line of cardiovascular medicine, anti-infective medicine and traditional Chinese medicine, while establishing a unified marketing platform, be weakened as a production base, and break the Taisheng, Kaiyuan original national agent model, by the company nationwide bidding, determining provincial distributors. Marketing reform led to the second line of products-Ning, amoxicillin flucloxacillin sodium, Qizhi dredging and other fast growth. 3. the product is worth looking forward to. The products of astragaloside injection, domestic exclusive, is used to treat angina, is currently the upgrading of the Astragalus species, expected next year completed phase 3, potential heavyweight varieties. Other important species include wuguteng lyophilized powder for injection, injectable yexintong, Clopidogrel bisulfate, etc. 4. the collection of funds is primarily used for expansion and medicinal herbs cultivation. This collection of funds into the surrounding 3.2 million mu of Matrine cultivation bases GAP medicinal herbs, Zhendong pharmacy, pharmaceutical pharmacy, Kaiyuan Taisheng capacity expansion. To antitumor medicines as the core product of national high-tech enterprises: the company is mainly engaged in the preparation of traditional Chinese medicine, research and development, production and sales, product line covering antitumor, cardio and resistance to infection, medication, etc., to "yanshu" as the core product, Changzhi city, Shanxi province first batch of high-tech enterprises. At present the company has three major production bases, 41 lines 11 large dosage form, 359. The actual control of the person as Chairman of Anping, release holding 57.8%. Part of the equity holding company executives. Leading products yanshu growth space larger: yanshu anticancer agents for pure herbs, mainly for the treatment of cancer pain and bleeding, as a national-level protection of traditional Chinese medicine, medical insurance r. 09 annual revenue, gross profit margin reached 3.7 95.5%, revenue, gross margin accounted for more than 71% and 87%, the parent company sales rate of about 62%. Rock solid tumor for the most comfortable, wide application, use the amount less than the competition, breed; company 2008 start technology upgrade research project, is the only through the Ministry of health, Ministry of science and technology to create "new drugs" major science major special "eleventh five-year" plan first topic creation review anti tumor. Major growth in the next three years: 1, rock sugar levels above 60% of hospital coverage about, there is still major upgrade space, technical upgrade of conducive to open up a line of large hospitals, it is expected that the growth rate of about 25%; 2, amoxicillin flucloxacillin sodium entered 17 shengyi, only 2 companies production, 2011 onwards will be rapid growth 3, Qizhi chaired by Academician Wang yy prescriptions for clinical and research work, the future is expected to become the company to another heavyweight varieties; 4, second line varieties-Ning, guanxinning is also expected to maintain rapid growth. Varieties more in development, see kindness cerebrovascular medicine astragali injections: enter the registration phase varieties 13, 15 preclinical varieties. And the second military medical university joint development of astragali has entered phase III, as Astragalus injections upgrade varieties, 2011 is expected to be completed clinical phase III. Fund-raising is mainly used for industrial chain consolidation and expansion of production capacity: intends to release 36 million shares, representing the total share capital after the release of 25%, to raise funds to vote for: 3.056 million GAP Matrine cultivation and traditional Chinese medical tablets processing, small capacity injection extension, frozen powder and sterile powder new, granule works, four projects. Expected 2010 ~ 2012 net profit increased by 42%, combined with a reasonable valuation 36.1 ~ 41.2 element, it is recommended that actively purchase: expected 2010 ~ 2012 pharmaceutical industry revenue grew 26%, 37% and 28%, net profit growth of 37%, 60% and 32%, diluted EPS 0.65 element, $ and $ 1.36 1.03. Considering the company's rapid growth and maturing of sales system, giving 2011 35 ~ 40 times forecast PE, we believe the company a reasonable valuation 36.1 ~ 41.2 element, it is recommended that the active application. Major advances in risk is lower than expected and high yanshu accounted for unmatchable product comparison �� is still a Matrine injection growth potential company mainly profitable varieties of Matrine injection for cancer pain and bleeding, 09, with annual sales of high gross margins 3.7 billion, up to 96% of total income and gross margin accounted for more than 71%, 87% of the domestic exclusive, is the national protection of traditional Chinese medicine and the national CPI Medicare varieties. Compared to similar products are relatively low cost, increase the amount of clinical trials are expected to be the fastest of 12 years end, secondary hospitals cover less than 50% of the expected future can maintain its rapid growth. Effect of digital marketing integration, the second line of products showed a good 07, 09, acquisitions Taisheng pharmacy, Kaiyuan pharmaceutical, to extend the product line of cardiovascular medicine, anti-infective medicine and traditional Chinese medicine, while establishing a unified marketing platform, be weakened as a production base, and breakTaisheng, Kaiyuan original national agent model, by the company nationwide bidding to determine provincial distributors. Marketing reform led to the second line of products-Ning, amoxicillin flucloxacillin sodium, Qizhi dredging and other fast growth. The product worth looking forward to in developing product astragaloside injection, exclusive, is used to treat angina, is currently the upgrading of the Astragalus species, expected next year completed phase 3, potential heavyweight varieties. Other important species include wuguteng lyophilized powder for injection, injectable yexintong, Clopidogrel bisulfate, etc. Collection of funds is primarily used for expansion and herbal planting this collection of funds into the surrounding 3.2 million mu of Matrine cultivation bases GAP medicinal herbs, Zhendong pharmacy, pharmaceutical pharmacy, Kaiyuan Taisheng capacity expansion. Risk tip 1) traditional Chinese medicine injection safety issues; 2) marketing channels to optimize integration risk. Profit forecasting and valuation expected 10 ~ 12 year net profit growth of 35% and 57%, 30%, EPS (diluted) 0.64, 1.00, 1.30 Yuan/unit. Company product Echelon construction better, rich product reserve, fist varieties flavescentis injection is still growth potential, the second line of products is expected to drive the company's rapid growth over the next three years into the "second growth period". Given the company a reasonable value